GlassScriptPhysician profile
Sarah Renfert
NPI 1932171600
$4,593.85
in general payments reported to CMS, 2019-2025
29 companies · $42.29 in 2025
The $42.29 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $359 · 2021: $881 · 2022: $580 · 2023: $1,070 · 2024: $1,121 · 2025: $42.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,053.89 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $748.63 | 2021-2024 | |
| Novo Nordisk INC | $629.28 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $258.80 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $219.44 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $216.31 | 2021-2024 | Rexulti |
| Amgen INC. | $202.07 | 2022-2024 | Evenity, Prolia |
| Eisai INC. | $179.28 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $139.41 | 2019-2024 | Xarelto |
| Pfizer INC. | $127.22 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $96.64 | 2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.14 | 2021-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $78.61 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $77.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.70 | 2023-2024 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $59.23 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Sobi, INC | $58.32 | 2023-2024 | |
| Exact Sciences Corporation | $47.57 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $47.30 | 2024 | |
| Lundbeck LLC | $24.23 | 2024 | Rexulti |
| Allergan, INC. | $22.67 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.55 | 2023 | |
| Ucb, INC. | $20.17 | 2023 | Cimzia |
| Mylan Specialty L.P. | $19.98 | 2024 | Yupelri |
| Genzyme Corporation | $19.41 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.62 | 2019 | |
| Shire North American Group INC | $16.28 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.06 | 2021 | |
| Glaxosmithkline, LLC. | $13.47 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Renfert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.